New weight-loss drug delivers twice as much weight loss: In the US, an overweight drug twice as effective as Ozampic was found Drug major Eli Lilly said its experimental weight-loss drug, retatrutide, showed stronger effects than the maximum dose of Ozampic. In the Phase 3 study, over 80 weeks, patients on retatrutide lost an average of 20-21.5 kg, while patients on Ozampi lost about 9.5 kg. The drug was also better at reducing blood sugar-related A1C and improving some measures of blood pressure and cholesterol. The company clarified that retrotide acts on three hormones at the same time, related to appetite, sugar levels and fat burning. In comparison, many known drugs work with only one or two of these mechanisms. Eli Lilly plans to apply for FDA approval in early 2027. ".

New weight-loss drug delivers twice as much weight loss: In the US, an overweight drug twice as effective as Ozampic was found Drug major Eli Lilly said its experimental weight-loss drug, retatrutide, showed stronger effects than the maximum dose of Ozampic. In the Phase 3 study, over 80 weeks, patients on retatrutide lost an average of 20-21.5 kg, while patients on Ozampi lost about 9.5 kg. The drug was also better at reducing blood sugar-related A1C and improving some measures of blood pressure and cholesterol. The company clarified that retrotide acts on three hormones at the same time, related to appetite, sugar levels and fat burning. In comparison, many known drugs work with only one or two of these mechanisms. Eli Lilly plans to apply for FDA approval in early 2027. ".